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Abstract
Telomerase is an RNA-dependent DNA polymerase that synthesizes telomeric DNA. Its activity is
not detectable in most somatic cells but it is reactivated during tumorigenesis. In most cancers, the
combination of hTERT hypermethylation and hypomethylation of a short promoter region is
permissive for low-level hTERT transcription. Activated and malignant lymphocytes express high
telomerase activity, through a mechanism that seems methylationin-dependent. The aim of this
study was to determine which mechanism is involved in the enhanced expression of hTERT in
lymphoid cells. Our data confirm that in B cells, some T cell lymphomas and non-neoplastic
lymph nodes, the hTERT promoter is unmethylated. Binding sites for the B cell-specific
transcription factor PAX5 were identified downstream of the ATG translational start site through
EMSA and ChIP experiments. ChIP assays indicated that the transcriptional activation of hTERT
by PAX5 does not involve repression of CTCF binding. In a B cell lymphoma cell line, siRNA-
induced knockdown of PAX5 expression repressed hTERT transcription. Moreover, ectopic
expression of PAX5 in a telomerase-negative normal fibroblast cell line was found to be sufficient
to activate hTERT expression. These data show that activation of hTERT in telomerase-positive B
cells is due to a methylation-independent mechanism in which PAX5 plays an important role.
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Introduction
The telomerase enzyme allows germ cells, stems cells and cancer cells to divide indefinitely
[1]. Human telomerase possesses a highly regulated subunit called telomerase reverse
transcriptase (hTERT), which is the limiting factor for its activity [2,3]. The hTERT
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expression is nearly imperceptible in the majority of differentiated somatic cells, which lead
to inevitable telomeric attrition and subsequently cellular senescence. High levels of hTERT
are detected in proliferative somatic cells such as endometrial tissues or activated
lymphocytes, but also in most immortalized and cancer cells.
hTERT transcription has been shown to be influenced by numerous activators and inhibitors,
such as c-Myc, Sp1, Hif-1, Mbi-1, USF1/2, oestrogen response element, p53, Mad1,
myeloid-specific zinc finger protein 2 (MZF-2), TGFβ, Wilms’ tumour 1 (WT1) and CTCF
[4–6]. In addition, a possible role of DNA methylation in hTERT transcription regulation
can be expected, as the hTERT promoter is situated within a dense CG-rich CpG island. In
normal somatic cells the hTERT promoter is unmethylated, although the transcription of the
gene is repressed. However, in most cancer cells, hypermethylation of this region correlates
with expression of the gene and with perceptible telomerase activity [7–10]. This apparent
contradiction with the classical mechanism of transcriptional repression by DNA
methylation was recently clarified. DNA methylation exhibits a dual role in hTERT
transcriptional regulation by interfering with the binding of inhibitors, such as the CTCF
transcription factor, and by partial hypomethylation of the core promoter, which allows the
hTERT gene to be permissive for transcription [11]. Furthermore, the absence of
methylation in association with active chromatin marks around the transcription start site of
hTERT indicates that expression and DNA methylation patterns of the hTERT promoter are
not in contradiction to the general model of gene silencing mediated by DNA methylation
[12].
In a small subset of telomerase-positive tumours, hTERT expression appears to be regulated
by a methylation-independent mechanism [12–14]. For example, the hTERT promoter is
methylated in only 30% of ovarian cancers, almost all of which are telomerase-positive [13].
Cells of the lymphoid system also seem to escape methylation-dependent mechanism of
hTERT regulation. Leukaemias and lymphomas, including B cell chronic lymphocytic
leukaemia (CLL), express high levels of telomerase but exhibit low levels of hTERT
promoter methylation [14]. More recently, acute myeloid leukaemia (HL-60) and Burkitt’s
lymphoma (Raji) cell lines, as well as normal lymphocytes, were found to have
hypomethylated hTERT promoters [12].
B cells exhibit notably longer telomeres than any other blood cell population, such as T
cells, natural killer cells and monocytes [15]. B cells in the germinal centre of tonsils have
longer telomeres compared to naïve and memory B cells [16]. As expected, low levels of
telomerase activity are observed in naïve and memory B cells, in contrast to germinal centre
B cells that exhibit high telomerase activity [16,17].
Paired box (PAX) proteins include nine members that are important regulators in early
development for tissue specificity [18]. Once bound to DNA, PAX proteins can play the role
of transcriptional activators or repressors [19–21]. Deregulation of PAX genes has been
associated with a variety of cancers, including astrocytoma, medulloblastoma, lymphoma
and Wilm’s tumour [22,23]. Moreover, PAX expression has been suggested to be essential
for survival of cancer cells. Recently, PAX8 has been implicated in the activation of hTERT
and hTR promoters, which in turn activate telomerase in glioma [24]. PAX2, PAX5 and
PAX8 belong to the same subgroup and thus could impact on hTERT regulation in a tissue-
specific manner. During B cell development, the PAX5 gene is expressed in early B cell
precursors (pro-B cells) and continues to be expressed up to mature B cells, but not in
terminally differentiated plasma cells [25,26]. As a consequence, PAX5 expression is used
as a lineage-specific marker in B cells neoplasms [27,28]. PAX5 has been shown to promote
the expression of target genes encoding crucial components of the (pre)BCR signalling
cascade, such as the receptor signalling chain Igα, also called CD79a and mb-1 [29,30], the
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costimulatory receptor CD19 [21,31] and the central adaptor protein BLNK [32]. PAX5 also
facilitates the VH–DJH recombination step and can activate other transcription factor genes
[33].
Our working hypothesis for the experiments reported in this paper was that hTERT
regulation in B cells is methylation-independent. To confirm our hypothesis, methylation
status of the hTERT promoter was investigated in normal and malignant lymphoid tissues.
Then, the B cell-specific factor PAX5 was considered for its participation in the induction of
hTERT expression in telomerase-positive B cells.
Experimental procedures
Cell culture
The Burkitt’s lymphoma cell lines Daudi and Ramos and the pre-B cell leukaemia line
Nalm6 were kindly provided by Dr Benedicte Baisse (CHUV, Lausanne, Switzerland). The
Burkitt line, Raji, was kindly provided by Apoxis (Lausanne, Switzerland). HeLa (cervical
adenocarcinoma), PC-3 (prostate adenocarcinoma) and BJ (normal fibroblasts) cells were
obtained from ATCC (Manassas, VA, USA). Cell lines were cultured in the medium
recommended by ATCC.
Tissue samples
The lymphomas and normal tissues came from the files of the Institute of Pathology of
Lausanne. The samples included: four histologically non-neoplastic lymphoid tissues (two
lymph node biopsies and two tonsil biopsies); six B cell non-Hodgkin lymphomas (NHLs),
comprising three high-grade and three low-grade NHLs; and six T cell NHLs. All diagnoses
were confirmed by a pathologist (RB). The lymphoma cases were selected to ensure that
sufficient populations of T or B cells were present. The use of human tissues for this study
was done according to the guidelines of the local ethics committee.
RT–PCR
Total RNA of frozen tissues and cultured cells was extracted using Trizol-LS (Invitrogen,
Basel, Switzerland) according to the manufacturer’s protocol. The extraction protocol for
fixed tissues was described previously [34]. RT–PCRs were performed using Super- Script
One-Step RT–PCR or Quantitative RT–PCR ThermoScript™ One-Step System (Invitrogen)
(for primers and RT–PCR for each individual gene, see Supporting information, Table S1).
DNA methylation analysis
DNA was extracted from frozen and fixed tissues and cultured cells using the DNeasy tissue
kit (Qiagen). DNA (2 µg) was modified with sodium bisulphite and used to amplify a 224 bp
fragment of the hTERT promoter, as previously described [35]. PCR products were analysed
by a methylation-sensitive dotblot assay (MS-DBA) [35] and confirmed by direct
sequencing [9] and methylation-sensitive single-strand conformation analysis (MS-SSCA)
[36,37].
Electrophoretic mobility shift assay (EMSA)
Oligonucleotides of the hTERT exonic region and the CD79A promoter region (hTERT,
sense, 5′-GCTGGTGCAGCGCGGGGACCCGGCGGCTTT-3′; CD79A, sense 5′-
AGCGAGGGCCACTGGAGCCCATCTCCGGGG-3′) were labelled with the DIG-
Oligonucleotide 3′-End Labelling Kit (Roche). Gel shift reactions were performed using the
DIG Gel Shift Kit (Roche) with 0.5 pmol DIG-labelled oligonucleotide and 5 µg Nalm6 or
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Raji cell extracts. A supershift assay was performed with a PAX5 rabbit antibody (Active
Motif, Carlsbad, USA) on Raji cell extracts, according to the manufacturer’s protocol.
Chromatin immunoprecipitation (ChIP)
ChIP assays were performed using EZ ChIP (Upstate Biotechnology, Lake Placid, NY,
USA), following the manufacturer’s instructions with some modifications. After
crosslinking with 1% formaldehyde and sonication to shear DNA, lysates from 2 × 106 cells
(PAX5) or 4 × 106 cells (CTCF) were diluted in ChIP dilution buffer for
immunoprecipitation or stored at 4 °C to be directly uncrosslinked and purified (DNA input
fraction). Magnetic beads (40 µl, Dynabeads Protein G, Invitrogen) were incubated for 1 h at
room temperature in 60 µl of the blocking solution with either 2 µg goat polyclonal anti-
PAX5 antibody (Santa Cruz, CA, USA), 10 µg mouse polyclonal anti-CTCF antibody
(Rockville, MD, USA) or without antibody. After washing and incubation overnight at 4 °C
with the chromatin solution, the beads were washed twice with the following solutions: low-
salt, high-salt, LiCl and finally Tris-EDTA (TE). The eluate was then resuspended in 200 µl
5% Chelex solution and incubated for 10 min at 100 °C to reverse the protein–DNA
crosslinks. After purification, the immunoprecipitated DNA was analysed by quantitative
real-time PCR with specific primers (see Supporting information, Table S2). The human
CTCF-binding site N, a MYC insulator site (MYC-N), and H19 were used as positive
controls and a CTCF non-binding site, G of MYC (MYC-G) was used as a negative control
[38,39]. For chromatin immunoprecipitation of PAX5, CD19, which is a well-known target
of PAX5, was used as a positive control, whereas KRAS, which does not contain PAX5
binding sites, was used as a negative control.
Immunohistochemistry (IHC)
Antigen retrieval was performed using a pressure cooker for 2 min in 10 mM sodium citrate
buffer, pH 6. The slides were incubated overnight at 4 °C with the anti-TERT antibody (1 :
50, EST21-A; Alpha Diagnostic International, San Antonio, TX, USA), the anti-PAX5
monoclonal antibody (1 : 50, BD Biosciences Pharmingen, San Jose, CA, USA) or the CD3
monoclonal antibody (1 : 1, Novocastra, Newcastle upon Tyne, UK). After washing, the
EnVision+ System – HRP AEC (TERT) or the EnVision+ Peroxidase rabbit followed by
DAB staining (PAX5 and CD3) were used according to the manufacturer’s instructions
(Dako, Glostrup, Denmark). The slides were then counterstained with haematoxylin.
Transient transfection
Jet PEI transfection reagent (2 µl) (Polyplus-transfection, Illkirch, France) was used to
transfect, in 105 normal fibroblast BJ cells, 2 µg PAX5 expression plasmid (phPAX5, a kind
gift from Professor M Busslinger, Research Institute of Molecular Pathology, Vienna,
Austria) [40]. Cells treated the same way but without plasmid were used as a transfection
control. Dnase extraction and total RNA extraction were performed 48 h after transfection.
Transfection of siRNA
A double-stranded annealed Stealth RNAi oligonucleotide targeting PAX5 was designed by
Invitrogen software (sense, 5′-GAGGAUAGUGGAACUUGCUCAUCAA-3′). A non-
specific fluorescent siRNA (Invitrogen) was used as a control. Transfection of 130 pM
siRNA oligonucleotides in 4 × 106 Raji cells was performed with Amaxa Nucleofector
(Amaxa Biosystems, Cologne, Germany) according to the manufacturer’s protocol. The
efficiency of RNA silencing was checked by western blot with PAX5 antibody (BD
Biosciences, Erembodegem, Belgium) and confirmed by quantitative RT–PCR.
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Quantitative RT–PCRs were performed on a Rotorgene 6000 cycler (Corbett Research,
Sydney, Australia). hTERT and PAX5 mRNAs were amplified using the Quantitative RT–
PCR Thermoscript One-Step System (Invitrogen) (the primers and probes are described in
the Supporting information, Table S3). CD19 and β-actin were amplified by the same
enzymes, but with 1.25 µM SYTO 9 fluorescent dye (Invitrogen) instead of the labelled
probes. The relative level of each mRNA was calculated on the basis of the two standard
curve relative quantification method. Gene expressions were normalized to β-actin and to
the cells transfected with the non-coding siRNA. At least two independent determinations of
fold differences were used to calculate the average fold difference values and associated
standard deviations (SDs).
Results
In lymphoid cells, a hypomethylated hTERT promoter allows hTERT expression
To define the methylation status of the hTERT promoter in lymphoid tissues, we analysed
six primary B cell lymphomas, six primary T cell lymphomas and four non-malignant
lymphoid tissues. Four human lymphoid tumour cell lines were also investigated. RT–PCR
analysis confirmed that hTERT transcripts were present in all the lymphoma tissues and cell
lines as well as in the non-neoplastic lymphoid tissues (Figure 1A). The β-actin gene was
simultaneously amplified as a control.
Using MS-DBA, we next explored the methylation status of the hTERT promoter. In B cell
lymphomas and non-neoplastic lymphoid tissues, the hTERT promoter was unmethylated,
while it was hypermethylated in half of the T cell lymphomas (Figure 1B). The hTERT
promoter was methylated in Daudi cells but unmethylated in the other three cell lines (Raji,
Ramos and Nalm6). Direct sequencing and MS-SSCA confirmed the results obtained by
MS-DBA (data not shown). To summarize, in some T cell lymphomas hTERT expression
goes along with hTERT promoter methylation, as is the case for most solid tumours. In
transformed B cells and non-neoplastic lymphocytes, however, hTERT is expressed in the
presence of a hypomethylated promoter. In this situation, hTERT expression must be
regulated by a methylation-independent mechanism.
Putative PAX5 binding sites are present in the hTERT gene
To determine whether transcription factors specific to lymphoid cells might be involved in
hTERT regulation, we searched for new transcription factor binding sites using
MatInspector software (http://www.genomatix.de/matinspector.html). MatInspector revealed
two potential binding sites for PAX5, also known as B cell-specific activator protein
(BSAP), a transcription factor involved in B cell differentiation and function [25,26], from
+110 to +137 bp and +489 to +516 bp downstream of the ATG translational start site
(Figure 2A). PAX5 binding sites match the consensus sequence at 9 and 11 out of 15
positions, for exon 1 and exon 2, respectively (Figure 2B). This suggested that PAX5 might
be involved in the regulation of hTERT transcription in lymphoid cells.
PAX5 binds the hTERT CpG island in vitro and in vivo
To determine whether the predicted PAX5 binding sites in the hTERT exon were authentic,
we first performed EMSAs using extracts from Raji cells. A specific band for PAX5 was
obtained with the CD79A oligonucleotide (Figure 3A, lane 1), which served as a positive
control [21,41]. A similar band was obtained with the hTERT probe (lane 2). To check the
specificity of the band, cold competitor oligonucleotides were added to the labelled hTERT
probe. A 100-fold molar excess of CD79A and hTERT competitors resulted in almost
complete inhibition of PAX5 binding (lanes 4 and 6). The same results were obtained with
Nalm6 extracts (data not shown). A 5–150-fold increase in the amount of cold CD79A probe
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also resulted in a progressive inhibition of binding (Figure 3B). Competitive EMSA, with an
oligonucleotide in which four specific bases were mutated, did not eliminate PAX5 binding
(Figure 3A, lane 5), indicating that PAX5 binding was specific. Pre-incubation of Raji cell
extracts with a PAX5-specific antibody resulted in a supershifted band (Figure 3A, lane 7),
confirming that PAX5 does bind to the predicted target sequence in the first exon of hTERT.
To determine whether PAX5 bound to the hTERT gene under physiological conditions,
chromatin immunoprecipitation (ChIP) experiments were performed, using Nalm6 and Raji
cells. DNA samples isolated from the input, the anti-PAX5-bound and the no-antibody
fractions were analysed by quantitative real-time PCR. CD19 is a well-known target of
PAX5 [31] and was used as positive control. The results indicated an approximately 10-fold
enrichment of hTERT exon 1 when normalized with the negative control KRAS gene, and
around eight-fold enrichment of hTERT exon 2 (Figure 3D). Enrichment of the CD19 gene
was about three to four times greater than that for hTERT, which was not surprising, as the
binding of PAX5 to the CD19 target sequences is very strong. In the no-antibody fraction,
no enrichment was detected with either hTERT or CD19 (data not shown). Thus, PAX5 is
bound in vivo to the first and the second exons of hTERT, providing strong evidence that
PAX5 could be involved in the transcriptional regulation of the gene in B cells.
PAX5 does not inhibit binding of CTCF to hTERT in vivo
A possible explanation for the effect of PAX5 on hTERT expression could be that it
interferes with CTCF-binding to the hTERT promoter. The CTCF transcription factor was
found to be essential for repression of hTERT transcription in a variety of normal somatic
cells [6]. As PAX5 binding sites lie downstream CTCF target sequences (Figure 2), we
therefore performed ChIP analysis to analyse CTCF binding. In Raji cells, hTERT exon 1
was enriched approximately four-fold compared to the negative control, which is in the
same range as in the two positive controls, MYC-N and H19 (Figure 4). After transfection
with a PAX5 siRNA, a strong reduction in the binding of PAX5 was observed on hTERT
and CD19 (Figure 4B), whereas chromatin immunoprecipitation of CTCF did not reveal any
significant change in the binding of CTCF to hTERT (Figure 4A). Thus, PAX5 binding to
the hTERT exonic region does not block CTCF binding.
hTERT and PAX5 have similar patterns of expression in B cell lymphomas and the B cell
areas of non-neoplastic lymphoid tissues
PAX5 is a specific marker for all stages of B cell differentiation except for plasma cells [42].
In our series, PAX5 mRNA was detected by RT–PCR in all B and T cell NHLs, as well as in
non-neoplastic lymphoid tissues and cell lines. The presence of PAX5 mRNA in the T cell
lymphomas could be due to the presence of normal B cells in the tumour tissues.
By IHC of consecutive sections, hTERT and PAX5 were both detected in the same regions
of the six B cell lymphomas, suggesting that they were present in the same tumour cells
(Figure 5A, B). The T cells were identified by CD3 expression. In B cell lymphomas, the
normal T cells did not appear to express either PAX5 or hTERT (Figure 5A, C). In the four
non-neoplastic lymphoid tissues, both PAX5 and hTERT were expressed in germinal centre
B cells and B cells of the mantle zone (Figure 5G, H), whereas CD3+ T cells were PAX5-
and hTERT-negative (Figure 5G–I). The expression of hTERT observed in germinal centre
and mantle zone was concordant with the published data on telomerase activity [16]. In the
six investigated T cell lymphomas, hTERT was expressed in the CD3+ neoplastic T cells
(Figure 5D, F) while PAX5 was not (Figure 5E, F). As expected, in T cell lymphomas,
PAX5 was only expressed in normal B cells and therefore PAX5 had no role in activating
hTERT expression in tumour T cells. In summary, PAX5 and hTERT co-localize in normal
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and malignant B cells, supporting the suggestion that PAX5 might be involved in hTERT
activation in these cells.
Suppression of PAX5 by siRNA represses hTERT transcription in telomerase-positive cells
To determine whether a reduction in PAX5 expression would be associated with a change in
hTERT expression, we transfected Raji cells with a PAX5 siRNA. After transfection, the
down-regulation of PAX5 protein was confirmed by western blot, while the levels of PAX5,
hTERT and CD19 transcripts were monitored by quantitative RT–PCR. Cells transfected
with a scrambled siRNA were used as a control. Twentyfour hours after transfection, PAX5
transcript levels were reduced ~50% in association with significant reductions in the levels
of CD19 and hTERT expression (~30%) (Figure 6A). After 48 h, PAX5 transcripts were
reduced by 77% in association with reductions of 57% and 64% in transcripts for CD19 and
hTERT, respectively. These studies showed that inhibition of PAX5 leads to a strong down-
regulation of hTERT expression, indicating that PAX5 is essential for hTERT expression in
B cells.
PAX5 activates hTERT transcription in normal telomerase-negative cells
To determine whether ectopic expression of PAX5 could activate hTERT expression in
normal telomerase-negative cells, we transfected normal BJ fibroblasts with a PAX5
expression plasmid. RT–PCR and western blot analyses of PAX5 expression 40 h post-
transfection confirmed the siRNA silencing efficiency (Figure 6A). RT–PCR analyses of
transcripts for CD19, an established target of PAX5, showed substantial expression in the
transfected cells. These data are in agreement with previous studies demonstrating that
ectopic expression of PAX5 led the up-regulation to CD19 and other PAX5-target genes
[21,43]. Interestingly, the transfected cells expressed hTERT transcripts at similar levels as
CD19. The level of expression of hTERT and CD19 was apparently lower in BJ than in Raji
cells, this could be explained by the absence in transfected BJ cells of specific transcription
factors necessary for a high level of expression of these genes. Non-transfected and mock-
transfected BJ cells did not express transcripts of PAX5, CD19 or hTERT. This experiment
showed that ectopic expression of PAX5 is sufficient to activate hTERT transcription in
normal somatic cells.
Discussion
In the present study, we showed that hTERT is transcribed in association with the
unmethylated 5′ region in B cells, B cell lymphomas and B cell lymphoma cell lines,
defining a novel methylation-independent mode of hTERT regulation. EMSA and ChIP
assays identified two binding sites in hTERT for the B cell-specific transcription factor
PAX5. These sites lie downstream of the ATG translational start site and are located in the
first exon and at the beginning of the second exon of hTERT. Moreover, in B cells,
decreasing PAX5 expression resulted in a significant reduction in hTERT expression.
Importantly, we showed that ectopic expression of PAX5 in telomerase-negative normal cell
lines is sufficient to activate hTERT expression. Taken together, these data strongly support
a role for PAX5 in the transcriptional activation of hTERT in B cells. Validation of our
observations by functional studies will be important.
hTERT is a new PAX5 target, which has no direct link to B cell differentiation, in contrast
to the well-known PAX5 target genes. Among the principal targets of PAX5, three genes,
CD79A, CD19 and PDCD1 (PD-1), code for cell surface molecules involved in signal
transduction, while the products of two other target genes, MYCN (N-Myc) and LEF1, are
nuclear transcription factors [31,40]. About 170 PAX5-activated genes have been identified
[44]. These genes mediate diverse biological functions in B cells, such as adhesion,
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migration, signalling and germinal-centre B cell formation, and demonstrate the pleiotropic
role of PAX5 in control of the B-lineage commitment.
PAX8, which belongs to the same subgroup of PAX proteins as PAX5, has been implicated
in the activation of hTERT in glioma [24]. PAX8 failed to activate the hTERT promoter in
telomerase-negative primary cell lines, and other factors seem to be necessary for the
expression of hTERT. In contrast, activation of PAX5 was sufficient to initiate the
transcription of hTERT in telomerase-negative primary cell lines. Apparently, the action of
PAX5 on hTERT is very different from that of PAX8. PAX8 mainly seems to act on the
formation of the transcription complex, whereas the major role of PAX5 in transcriptional
activation does not seem to be to recruit basal transcription machinery, but is likely to
modulate the structure of local chromatin, allowing other sequence-specific factors to
activate transcription. Indeed, PAX5 can activate transcription through association with
chromatin effector enzymes such as DAXX, CREB-binding protein (CBP) and GCN5,
which possess histone acetyltransferase (HAT) activity. PAX5 can also interact with BRG1,
a catalytic component of the Swi/Snf chromatin remodelling complexes [45]. On the other
hand, CTCF directly binds to SIN3A, which condenses chromatin and prevents transcription
by recruitment of histone deacetylase (HDAC) activity [46]. Therefore, the simultaneous
binding of CTCF and PAX5 on hTERT exons might produce opposing effects on chromatin:
the recruitment of histone modification and nucleosome remodelling activities by PAX5
might antagonize chromatin-mediated transcriptional repression by CTCF. Additional
studies need to be performed to more accurately understand how CTCF and PAX5 interact
in regulating hTERT expression.
In summary, we describe a methylation-independent mechanism of hTERT regulation that
occurs in telomerase-positive B cells. In these cells, hTERT is a novel target of PAX5,
which is essential for B cell development and function. According to our data, in B cells,
PAX5 also participates in cellular mechanisms underlying cell immortality by up-regulating
hTERT gene expression.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
This work was supported by grants from the Swiss National Science Foundation (Grants 3100A0-101732 and
3100A0-113505) and in part by the Intramural Research Program of the NIH, National Institute of Allergy and
Infectious Diseases.
References
1. Meeker AK, Coffey DS. Telomerase: a promising marker of biological immortality of germ, stem,
and cancer cells. A review. Biochemistry (Mosc). 1997; 62:1323–1331. [PubMed: 9467857]
2. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, et al. hEST2, the putative
human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization.
Cell. 1997; 90:785–795. [PubMed: 9288757]
3. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, et al. Telomerase
catalytic subunit homologs from fission yeast and human. Science. 1997; 277:955–959. [PubMed:
9252327]
4. Goueli BS, Janknecht R. Regulation of telomerase reverse transcriptase gene activity by upstream
stimulatory factor. Oncogene. 2003; 22:8042–8047. [PubMed: 12970752]
5. Poole JC, Andrews LG, Tollefsbol TO. Activity, function, and gene regulation of the catalytic
subunit of telomerase (hTERT). Gene. 2001; 269:1–12. [PubMed: 11376932]
Bougel et al. Page 8
J Pathol. Author manuscript; available in PMC 2012 August 17.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
6. Renaud S, Loukinov D, Bosman FT, Lobanenkov V, Benhattar J. CTCF binds the proximal exonic
region of hTERT and inhibits its transcription. Nucleic Acids Res. 2005; 33:6850–6860. [PubMed:
16326864]
7. Dessain SK, Yu HY, Reddel RR, Beijersbergen RL, Weinberg RA. Methylation of the human
telomerase gene CpG island. Cancer Res. 2000; 60:537–541. [PubMed: 10676632]
8. Devereux TR, Horikawa I, Anna CH, Annab LA, Afshari CA, Barrett JC. DNA methylation
analysis of the promoter region of the human telomerase reverse transcriptase (hTERT) gene.
Cancer Res. 1999; 59:6087–6090. [PubMed: 10626795]
9. Guilleret I, Yan P, Grange F, Braunschweig R, Bosman FT, Benhattar J. Hypermethylation of the
human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity. Int J Cancer.
2002; 101:335–341. [PubMed: 12209957]
10. Nomoto K, Maekawa M, Sugano K, Ushiama M, Fukayama N, Fujita S, et al. Methylation status
and expression of human telomerase reverse transcriptase mRNA in relation to hypermethylation
of the p16 gene in colorectal cancers as analyzed by bisulfite PCR–SSCP. Jpn J Clin Oncol. 2002;
32:3–8. [PubMed: 11932355]
11. Renaud S, Loukinov D, Abdullaev Z, Guilleret I, Bosman FT, Lobanenkov V, et al. Dual role of
DNA methylation inside and outside of CTCF-binding regions in the transcriptional regulation of
the telomerase hTERT gene. Nucleic Acids Res. 2007; 35:1245–1256. [PubMed: 17267411]
12. Zinn RL, Pruitt K, Eguchi S, Baylin SB, Herman JG. hTERT is expressed in cancer cell lines
despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin
around the transcription start site. Cancer Res. 2007; 67:194–201. [PubMed: 17210699]
13. Widschwendter A, Muller HM, Hubalek MM, Wiedemair A, Fiegl H, Goebel G, et al. Methylation
status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer.
Gynecol Oncol. 2004; 93:407–416. [PubMed: 15099954]
14. Bechter OE, Eisterer W, Dlaska M, Kuhr T, Thaler J. CpG island methylation of the hTERT
promoter is associated with lower telomerase activity in B-cell lymphocytic leukemia. Exp
Hematol. 2002; 30:26–33. [PubMed: 11823034]
15. Martens UM, Brass V, Sedlacek L, Pantic M, Exner C, Guo Y, et al. Telomere maintenance in
human B lymphocytes. Br J Haematol. 2002; 119:810–818. [PubMed: 12437664]
16. Weng NP, Granger L, Hodes RJ. Telomere lengthening and telomerase activation during human B
cell differentiation. Proc Natl Acad Sci USA. 1997; 94:10827–10832. [PubMed: 9380719]
17. Hu BT, Lee SC, Marin E, Ryan DH, Insel RA. Telomerase is upregulated in human germinal
center B cells in vivo and can be re-expressed in memory B cells activated in vitro. J Immunol.
1997; 159:1068–1071. [PubMed: 9233598]
18. Underhill DA. Genetic and biochemical diversity in the Pax gene family. Biochem Cell Biol. 2000;
78:629–638. [PubMed: 11103953]
19. Busslinger M, Klix N, Pfeffer P, Graninger PG, Kozmik Z. Deregulation of PAX-5 by
translocation of the Emu enhancer of the IgH locus adjacent to two alternative PAX-5 promoters
in a diffuse large-cell lymphoma. Proc Natl Acad Sci USA. 1996; 93:6129–6134. [PubMed:
8650231]
20. Dorfler P, Busslinger M. C-terminal activating and inhibitory domains determine the
transactivation potential of BSAP (Pax-5) Pax-2 and Pax-8. EMBO J. 1996; 15:1971–1982.
[PubMed: 8617244]
21. Nutt SL, Morrison AM, Dorfler P, Rolink A, Busslinger M. Identification of BSAP (Pax-5) target
genes in early B-cell development by loss- and gain-of-function experiments. EMBO J. 1998;
17:2319–2333. [PubMed: 9545244]
22. Muratovska A, Zhou C, He S, Goodyer P, Eccles MR. Paired-box genes are frequently expressed
in cancer and often required for cancer cell survival. Oncogene. 2003; 22:7989–7997. [PubMed:
12970747]
23. Robson EJ, He SJ, Eccles MR. A PANorama of PAX genes in cancer and development. Nat Rev
Cancer. 2006; 6:52–62. [PubMed: 16397527]
24. Chen YJ, Campbell HG, Wiles AK, Eccles MR, Reddel RR, Braithwaite AW, et al. PAX8
regulates telomerase reverse transcriptase and telomerase RNA component in glioma. Cancer Res.
2008; 68:5724–5732. [PubMed: 18632625]
Bougel et al. Page 9
J Pathol. Author manuscript; available in PMC 2012 August 17.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
25. Barberis A, Widenhorn K, Vitelli L, Busslinger M. A novel B-cell lineage-specific transcription
factor present at early but not late stages of differentiation. Genes Dev. 1990; 4:849–859.
[PubMed: 2116362]
26. Nutt SL, Urbanek P, Rolink A, Busslinger M. Essential functions of Pax5 (BSAP) in pro-B cell
development: difference between fetal and adult B lymphopoiesis and reduced V-to-DJ
recombination at the IgH locus. Genes Dev. 1997; 11:476–491. [PubMed: 9042861]
27. Mhawech-Fauceglia P, Saxena R, Zhang SZ, Terracciano L, Sauter G, Chadhuri A, et al. Pax-5
immunoexpression in various types of benign and malignant tumours: a high-throughput tissue
microarray analysis. J Clin Pathol. 2007; 60:709–714. [PubMed: 16837628]
28. Torlakovic E, Torlakovic G, Nguyen PL, Brunning RD, Delabie J. The value of anti-pax-5
immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell
marker. Am J Surg Pathol. 2002; 26:1343–1350. [PubMed: 12360049]
29. Fitzsimmons D, Hodsdon W, Wheat W, Maira SM, Wasylyk B, Hagman J. Pax-5 (BSAP) recruits
Ets proto-oncogene family proteins to form functional ternary complexes on a B-cell-specific
promoter. Genes Dev. 1996; 10:2198–2211. [PubMed: 8804314]
30. Nutt SL, Urbanek P, Rolink A, Busslinger M. Essential functions of Pax5 (BSAP) in pro-B cell
development: difference between fetal and adult B lymphopoiesis and reduced V-to-DJ
recombination at the IgH locus. Genes Dev. 1997; 11:476–491. [PubMed: 9042861]
31. Kozmik Z, Wang S, Dorfler P, Adams B, Busslinger M. The promoter of the Cd19 gene is a target
for the B-cell-specific transcription factor BSAP. Mol Cell Biol. 1992; 12:2662–2672. [PubMed:
1375324]
32. Schebesta M, Pfeffer PL, Busslinger M. Control of pre-BCR signaling by Pax5-dependent
activation of the BLNK gene. Immunity. 2002; 17:473–485. [PubMed: 12387741]
33. Fuxa M, Skok J, Souabni A, Salvagiotto G, Roldan E, Busslinger M. Pax5 induces V-to-DJ
rearrangements and locus contraction of the immunoglobulin heavy-chain gene. Genes Dev. 2004;
18:411–422. [PubMed: 15004008]
34. Guillou L, Coindre JM, Gallagher G, Terrier P, Gebhard S, Somerhausen ND, et al. Detection of
the synovial sarcoma translocation t(X; 18) (SYT; SSX) in paraffin-embedded tissues using
reverse transcriptase-polymerase chain reaction. A reliable and powerful diagnostic tool for
pathologists — a molecular analysis of 221 mesenchymal tumors fixed in different fixatives. Hum
Pathol. 2001; 32:105–112. [PubMed: 11172303]
35. Clement G, Benhattar J. A methylation sensitive dot blot assay (MS-DBA) for the quantitative
analysis of DNA methylation in clinical samples. J Clin Pathol. 2005; 58:155–158. [PubMed:
15677535]
36. Bian YS, Yan P, Osterheld MC, Fontolliet C, Benhattar J. Promoter methylation analysis on micro-
dissected paraffin-embedded tissues using bisulfite treatment and PCR-SSCP. Biotechniques.
2001; 30:66–72. [PubMed: 11196322]
37. Bianco T, Hussey D, Dobrovic A. Methylation-sensitive, single-strand conformation analysis (MS-
SSCA): a rapid method to screen for and analyze methylation. Hum Mutat. 1999; 14:289–293.
[PubMed: 10502775]
38. Pugacheva EM, Tiwari VK, Abdullaev Z, Vostrov AA, Flanagan PT, Quitschke WW, et al.
Familial cases of point mutations in the XIST promoter reveal a correlation between CTCF
binding and pre-emptive choices of X chromosome inactivation. Hum Mol Genet. 2005; 14:953–
965. [PubMed: 15731119]
39. Renaud S, Pugacheva EM, Delgado MD, Braunschweig R, Abdullaev Z, Loukinov D, et al.
Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites
(BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF
and p53 transcription factors. Nucleic Acids Res. 2007; 35:7372–7388. [PubMed: 17962299]
40. Nutt SL, Morrison AM, Dorfler P, Rolink A, Busslinger M. Identification of BSAP (Pax-5) target
genes in early B-cell development by loss- and gain-of-function experiments. EMBO J. 1998;
17:2319–2333. [PubMed: 9545244]
41. Wheat W, Fitzsimmons D, Lennox H, Krautkramer SR, Gentile LN, McIntosh LP, et al. The
highly conserved β-hairpin of the paired DNA-binding domain is required for assembly of Pax–
Ets ternary complexes. Mol Cell Biol. 1999; 19:2231–2241. [PubMed: 10022910]
Bougel et al. Page 10
J Pathol. Author manuscript; available in PMC 2012 August 17.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
42. Jensen KC, Higgins JPT, Montgomery K, Kaygusuz G, van de Rijn M, Natkunam Y. The utility of
PAX5 immunohistochemistry in the diagnosis of undifferentiated malignant neoplasms. Mod
Pathol. 2007; 20:871–877. [PubMed: 17529924]
43. Cozma D, Yu D, Hodawadekar S, Azvolinsky A, Grande S, Tobias JW, et al. B cell activator
PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling. J Clin Invest.
2007; 117:2602–2610. [PubMed: 17717600]
44. Schebesta A, McManus S, Salvagiotto G, Delogu A, Busslinger GA, Busslinger M. Transcription
factor Pax5 activates the chromatin of key genes involved in B cell signaling, adhesion, migration,
and immune function. Immunity. 2007; 27:49–63. [PubMed: 17658281]
45. Gregory PD, Wagner K, Horz W. Histone acetylation and chromatin remodeling. Exp Cell Res.
2001; 265:195–202. [PubMed: 11302684]
46. Lutz M, Burke LJ, Barreto G, Goeman F, Greb H, Arnold R, et al. Transcriptional repression by
the insulator protein CTCF involves histone deacetylases. Nucleic Acids Res. 2000; 28:1707–
1713. [PubMed: 10734189]
47. Czerny T, Busslinger M. DNA-binding and transactivation properties of Pax-6: three amino acids
in the paired domain are responsible for the different sequence recognition of Pax-6 and BSAP
(Pax-5). Mol Cell Biol. 1995; 15:2858–2871. [PubMed: 7739566]
Bougel et al. Page 11
J Pathol. Author manuscript; available in PMC 2012 August 17.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1.
hTERT mRNA expression and hTERT methylation in lymphoid tissues and cell lines. (A)
Detection of hTERT expression by RT–PCR in six B cell lymphomas, six T cell
lymphomas, four non-neoplastic lymphoid tissues and four lymphoid cell lines. HeLa and
PC-3 cells were used as positive controls. Normal BJ fibroblasts were used as a negative
control. (B) Methylation analysis of the hTERT promoter by methyl-sensitive dot-blot assay
(MS-DBA). Hybridization with a TG probe revealed the non-methyl part of the PCR and
hybridization with a CG probe detected the methyl part of the PCR. A scale of methylation
(100%, 80%, 50%, 20% and 0%) was used to quantify the percentage of methylation found
in the different samples. 100* indicates that the 100% methylation possesses a residual
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background with the non-methyl probe. As control, HeLa and PC-3 harboured an hTERT
methylated promoter, whereas hTERT was unmethylated in BJ. The same samples used for
RT–PCR were tested for methylation
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Figure 2.
PAX5 binding sites in the hTERT gene. (A) Localization of putative transcription factor
binding sites on hTERT sequences from −401 to +600 bp flanking the ATG (+1). The main
transcriptional start sites are indicated by arrows. The ATG translational start site is
highlighted in grey. The exonic regions are underlined. Known binding sites of SP1, c-
MYC, E2F and CTCF are shown in small boxes. Potential binding sites of PAX5 predicted
by the MatInspector program are shown in large grey boxes. (B) Alignment of the hTERT,
CD79A and CD19 sequences with the PAX5 consensus recognition motif [47]. Consensus
nucleotides are shown in grey overlay. *Point mutations
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Figure 3.
In vitro and in vivo binding of PAX5 in Raji cells. (A) EMSAs were performed with DIG-
labelled oligonucleotides representing PAX5 binding sites on CD79A as a positive control
gene (lane 1) and on the hTERT gene (lanes 2–7). A negative control without extract was
performed (lane 3). An excess (100×) of unlabelled oligonucleotide (hTERT; CD79A) was
used in a competition assay for PAX5 binding to the labelled probes (lanes 4 and 6,
respectively). A competition assay was also performed with an hTERT oligonucleotide with
four mutations (hTERTm), as described in Figure 2B (lane 5). A supershift was performed
with a PAX5 antibody (lane 7, αPAX5). (B) A graduated competition with unlabelled
oligonucleotide (CD79A)was performed on Raji cellular extracts, with an excess (5×, 15×,
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50× and 150×) of unlabelled CD79A oligonucleotide and an excess (150×) of unlabelled
hTERT oligonucleotide. (C) Real-time PCR analysis of hTERT DNA fragments precipitated
in a chromatin immunoprecipitation (ChIP) assay by a PAX5 antibody in Nalm6 and Raji
cells. CD19 was used to detect specific PAX5 binding and KRAS was used to identify non-
specific interactions
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Figure 4.
ChIP of CTCF in Raji cells 48 h after transfection with either a control siRNA or a siRNA
against PAX5. (A) Analysis of hTERT DNA fragments precipitated in a CHIP assay by a
CTCF-antibody was performed by quantitative real-time PCR. MYC-N and H19 were used
to detect specific CTCF binding and MYC-G was used to identify non-specific interactions.
(B) Controls of PAX5 siRNA treatments. A western blot of PAX5 was performed to control
the efficiency of PAX5 siRNA treatment. A real-time PCR analysis of hTERT and CD19
DNA fragments precipitated in a ChIP assay by a PAX5 antibody was used to demonstrate
the efficiency of PAX5 siRNA treatment through the failing of PAX5 binding. KRAS was
used to identify non-specific interactions
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Figure 5.
Immunohistochemistry of hTERT, PAX5 and CD3. Representative images are shown at low
magnification (×10) and at high magnification (×40) in the insets. (A–C) B cell lymphoma;
(D–F) T cell lymphoma; (G–I) normal lymph node
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Figure 6.
The effect of activation or inactivation of PAX5. (A) Quantitative RT–PCR of PAX5,
hTERT and CD19 after transfection of a PAX5 siRNA into Raji cells. Quantitations were
performed 24 and 48 h after transfection. The relative amounts of each mRNA were
normalized to the amounts of mRNA after transfection of a scrambled siRNA compared
with β-actin. A western blot of PAX5 was performed to control the efficiency of PAX5
siRNA treatment 48 h after transfection. (B) Detection of PAX5, CD19 and hTERT
expression by RT–PCR before and after transfection of a PAX5 expression plasmid into
telomerase- and PAX5-negative BJ cells and in Raji-positive control cells. β-actin was used
as a control for the RT–PCR. Triplicates of the transfection experiments are shown
Bougel et al. Page 19
J Pathol. Author manuscript; available in PMC 2012 August 17.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
